1. Home
  2. CFBK vs ACOG Comparison

CFBK vs ACOG Comparison

Compare CFBK & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CF Bankshares Inc.

CFBK

CF Bankshares Inc.

HOLD

Current Price

$31.78

Market Cap

178.1M

Sector

Finance

ML Signal

HOLD

Logo Alpha Cognition Inc.

ACOG

Alpha Cognition Inc.

HOLD

Current Price

$8.45

Market Cap

185.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
CFBK
ACOG
Founded
1892
2000
Country
United States
Canada
Employees
N/A
71
Industry
Major Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
178.1M
185.1M
IPO Year
2005
N/A

Fundamental Metrics

Financial Performance
Metric
CFBK
ACOG
Price
$31.78
$8.45
Analyst Decision
Buy
Strong Buy
Analyst Count
2
2
Target Price
$31.50
$16.00
AVG Volume (30 Days)
100.8K
41.9K
Earning Date
05-08-2026
05-14-2026
Dividend Yield
1.23%
N/A
EPS Growth
30.58
N/A
EPS
0.77
N/A
Revenue
N/A
N/A
Revenue This Year
$31.99
$139.22
Revenue Next Year
$9.09
$134.48
P/E Ratio
$40.74
N/A
Revenue Growth
N/A
N/A
52 Week Low
$22.10
$4.50
52 Week High
$34.34
$10.88

Technical Indicators

Market Signals
Indicator
CFBK
ACOG
Relative Strength Index (RSI) 58.35 82.12
Support Level $28.40 $5.11
Resistance Level $31.70 N/A
Average True Range (ATR) 0.99 0.52
MACD -0.09 0.18
Stochastic Oscillator 47.77 90.45

Price Performance

Historical Comparison
CFBK
ACOG

About CFBK CF Bankshares Inc.

CF Bankshares Inc is engaged in the provision of a variety of financial services. It provides personalized business banking products and services, including commercial loans and leases, commercial and residential real estate loans, equipment leasing, SBA loans, and treasury management depository services. The revenues are derived principally from the interest and fees on loans originated and noninterest income generated on the sale of loans.

About ACOG Alpha Cognition Inc.

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

Share on Social Networks: